Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C16H16ClNO2S.C6H6O3S |
Molecular Weight | 479.997 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OS(=O)(=O)C1=CC=CC=C1.COC(=O)[C@@H](N2CCC3=C(C2)C=CS3)C4=CC=CC=C4Cl
InChI
InChIKey=CUZIJKLLBDXNFV-RSAXXLAASA-N
InChI=1S/C16H16ClNO2S.C6H6O3S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14;7-10(8,9)6-4-2-1-3-5-6/h2-5,7,9,15H,6,8,10H2,1H3;1-5H,(H,7,8,9)/t15-;/m0./s1
Molecular Formula | C16H16ClNO2S |
Molecular Weight | 321.822 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | C6H6O3S |
Molecular Weight | 158.175 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Clopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to inhibit blood clots in a variety of conditions such as peripheral vascular disease, coronary artery disease, and cerebrovascular disease. Clopidogrel is sold under the name Plavix by Sanofi and Bristol-Myers Squibb. Plavix (clopidogrel bisulfate) is an inhibitor of ADP-induced platelet aggregation acting by direct
inhibition of adenosine diphosphate (ADP) binding to its receptor and of the subsequent ADPmediated
activation of the glycoprotein GPIIb/IIIa complex. Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that
inhibits platelet aggregation. The active metabolite of clopidogrel selectively inhibits the
binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADPmediated
activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet
aggregation. This action is irreversible. Consequently, platelets exposed to clopidogrel’s active
metabolite are affected for the remainder of their lifespan (about 7 to 10 days). Platelet
aggregation induced by agonists other than ADP is also inhibited by blocking the amplification
of platelet activation by released ADP. Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
6.9 null [pKi] | |||
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PLAVIX Approved UsePlavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as
follows:
• Recent MI, Recent Stroke or Established Peripheral Arterial Disease
For patients with a history of recent myocardial infarction (MI), recent stroke, or established
peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint
of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.
• Acute Coronary Syndrome
-For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave
MI) including patients who are to be managed medically and those who are to be
managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix
has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or
stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or
refractory ischemia.
Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as
follows:
• Recent MI, Recent Stroke or Established Peripheral Arterial Disease
For patients with a history of recent myocardial infarction (MI), recent stroke, or established
peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint
of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.
• Acute Coronary Syndrome
-For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave
MI) including patients who are to be managed medically and those who are to be
managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix
has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or
stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or
refractory ischemia. Launch Date1997 |
|||
Primary | PLAVIX Approved UsePlavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as
follows:
• Recent MI, Recent Stroke or Established Peripheral Arterial Disease
For patients with a history of recent myocardial infarction (MI), recent stroke, or established
peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint
of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.
• Acute Coronary Syndrome
-For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave
MI) including patients who are to be managed medically and those who are to be
managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix
has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or
stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or
refractory ischemia. Launch Date1997 |
|||
Primary | PLAVIX Approved UsePlavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as
follows:
• Recent MI, Recent Stroke or Established Peripheral Arterial Disease
For patients with a history of recent myocardial infarction (MI), recent stroke, or established
peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint
of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.
• Acute Coronary Syndrome
-For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave
MI) including patients who are to be managed medically and those who are to be
managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix
has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or
stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or
refractory ischemia. Launch Date1997 |
|||
Preventing | PLAVIX Approved UsePlavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as
follows:
• Recent MI, Recent Stroke or Established Peripheral Arterial Disease
For patients with a history of recent myocardial infarction (MI), recent stroke, or established
peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint
of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.
• Acute Coronary Syndrome
-For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave
MI) including patients who are to be managed medically and those who are to be
managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix
has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or
stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or
refractory ischemia. Launch Date1997 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.521 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT02185534 |
75 mg single, oral dose: 75 mg route of administration: oral experiment type: single co-administered: |
CLOPIDOGREL plasma | Homo sapiens population: healthy age: sex: food status: |
|
15800 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
4600 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2520 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
1500 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.09 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT02185534 |
75 mg single, oral dose: 75 mg route of administration: oral experiment type: single co-administered: |
CLOPIDOGREL plasma | Homo sapiens population: healthy age: sex: food status: |
|
0.767 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT02185534 |
75 mg single, oral dose: 75 mg route of administration: oral experiment type: single co-administered: |
CLOPIDOGREL plasma | Homo sapiens population: healthy age: sex: food status: |
|
50600 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
9890 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
7440 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
3130 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
5.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
7.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
7.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
8.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2% |
unknown, unknown |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
600 mg 1 times / day multiple, oral Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
healthy, 20-45 years |
Other AEs: Uric acid abnormal... |
1650 mg single, oral Overdose |
unknown, 49 years |
|
600 mg 1 times / day multiple, oral Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, 59 years |
Disc. AE: Transaminases increased, Fever... AEs leading to discontinuation/dose reduction: Transaminases increased (1 patient) Sources: Fever (1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Uric acid abnormal | 5 patients | 600 mg 1 times / day multiple, oral Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
healthy, 20-45 years |
Fever | 1 patient Disc. AE |
600 mg 1 times / day multiple, oral Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, 59 years |
Transaminases increased | 1 patient Disc. AE |
600 mg 1 times / day multiple, oral Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, 59 years |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 169.0 |
no | |||
Page: 91, 169 |
no | |||
no | ||||
Page: 91, 169 |
no | |||
Page: 169.0 |
no | |||
Page: 91, 169 |
no | |||
Page: 169.0 |
no | |||
Page: 91, 169 |
no | |||
Page: 169.0 |
no | |||
Page: 91, 169 |
no | |||
Page: 169.0 |
no | |||
Page: 91, 169 |
no | |||
Page: 74.0 |
no | |||
weak | ||||
weak | ||||
yes [IC50 0.307 uM] | ||||
yes [IC50 6.25 uM] | ||||
Page: 91, 170 |
yes [Ki 28 uM] | |||
yes | ||||
Page: 22.0 |
yes | |||
yes | ||||
Page: 74.0 |
yes | |||
Page: 74.0 |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 168.0 |
likely | |||
Page: 168.0 |
likely | |||
Page: 168.0 |
likely | |||
Page: 168.0 |
no | |||
Page: 168.0 |
no | |||
no | ||||
no | ||||
no | ||||
no | ||||
yes [Km 181 uM] | ||||
yes [Km 19 uM] | ||||
yes [Km 20.9 uM] | ||||
yes [Km 5.61 uM] | ||||
yes | ||||
Page: 168.0 |
yes | |||
Page: 168.0 |
yes | |||
Page: 168.0 |
yes | |||
yes | ||||
Page: 74.0 |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Effect of clopidogrel on naproxen-induced gastrointestinal blood loss in healthy volunteers. | 1998 |
|
Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. | 1999 Aug |
|
Current oral antiplatelet agents to prevent atherothrombosis. | 2001 |
|
Benefit of ADP receptor antagonists in atherothrombotic patients: new evidence. | 2001 |
|
Atherothrombosis: a major health burden. | 2001 |
|
Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk. | 2001 Apr |
|
[Optimal platelet inhibition therapy in unstable angina pectoris and after coronary interventions]. | 2001 Apr |
|
Regular or "super-aspirins"? A review of thienopyridines or aspirin to prevent stroke. | 2001 Apr |
|
Antithrombotic drugs for secondary stroke prophylaxis. | 2001 Apr |
|
Clinical and angiographical follow-up after implantation of a 6--12 microCi radioactive stent in patients with coronary artery disease. | 2001 Apr |
|
[Acute heart attacks. Prognosis can be further improved]. | 2001 Apr 5 |
|
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. | 2001 Aug 18 |
|
Severe hypersensitivity associated with clopidogrel. | 2001 Aug 21 |
|
Newer antiplatelet therapies in stroke prevention. | 2001 Feb |
|
Antiplatelet therapy in the elderly. Aspirin, ticlopidine-clopidogrel, and GPIIb/GPIIIa antagonists. | 2001 Feb |
|
Antithrombotic and thrombolytic therapy for ischemic stroke. | 2001 Feb |
|
Comparison of effects of clopidogrel versus ticlopidine on platelet function in patients undergoing coronary stent placement. | 2001 Feb 1 |
|
Fatal aplastic anaemia associated with clopidogrel. | 2001 Feb 10 |
|
[Update on the treatment with platelet antiaggregation agents]. | 2001 Jan |
|
[Clopidogrel? Known or known?]. | 2001 Jan |
|
Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. | 2001 Jan 23 |
|
Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. | 2001 Jan 25 |
|
Clopidogrel (Plavix): hematological reactions. | 2001 Jan 9 |
|
Multiple intracranial aneurysms as delayed complications of an atrial myxoma: case report. | 2001 Jul |
|
Diffuse alveolar hemorrhage after clopidogrel use. | 2001 Jul |
|
Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population. | 2001 Jul 31 |
|
[Toxic skin reaction to clopidogrel]. | 2001 Jun |
|
Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. | 2001 Jun |
|
Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement: analysis of 5,678 patients with a four-week ticlopidine regimen. | 2001 Jun 15 |
|
[Acute coronary syndromes: an update. II. Coronary revascularization and risk stratification]. | 2001 Mar |
|
[Pharmacy clinics. Medication of the month. Clopidogrel (Plavix)]. | 2001 Mar |
|
Activation of Gi-coupled receptors releases a tonic state of inhibited platelet aggregation. | 2001 Mar |
|
Platelet CD40 ligand (CD40L)--subcellular localization, regulation of expression, and inhibition by clopidogrel. | 2001 Mar |
|
[Therapeutic aspects of cerebral ischemia]. | 2001 Mar 10 |
|
New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines. | 2001 May |
|
Orbofiban: an orally active GPIIb/IIIa platelet receptor antagonist. | 2001 May |
|
Edge stenosis after intracoronary radiotherapy: angiographic, intravascular, and histological findings. | 2001 May 1 |
|
P2y(12), a new platelet ADP receptor, target of clopidogrel. | 2001 May 4 |
|
Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban). | 2001 Oct 15 |
|
Coronary stent thrombosis: insights from the porcine coronary stent model. | 2001 Sep |
|
Effects of combining three different antiplatelet agents on platelets and leukocytes in whole blood in vitro. | 2001 Sep |
|
Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers. | 2001 Sep |
|
Adjunctive therapies in the cath lab. Subacute stent thrombosis developing twelve days after discontinuation of ticlopidine treatment. | 2001 Sep |
|
Endovascular brachytherapy for prophylaxis against restenosis after long-segment femoropopliteal placement of stents: initial results. | 2001 Sep |
Sample Use Guides
Recent MI, Recent Stroke, or Established Peripheral Arterial Disease
The recommended daily dose of is 75 mg once daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10077233
Incubation of human washed platelets with clopidogrel resulted in a time- (maximum effects after 30 min) and concentration-dependent (IC50 1.9+/-0.3 uM) inhibition of ADP (6 uM)-induced platelet aggregation. Clopidogrel (30 uM) did not inhibit collagen (2.5 ug ml(-1))-, U46619 (1 uM)- or thrombin (0.1 u ml(-1))-induced platelet aggregation.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:02:04 GMT 2025
by
admin
on
Mon Mar 31 19:02:04 GMT 2025
|
Record UNII |
BL9VGG8BHW
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EMA ASSESSMENT REPORTS |
CLOPIDOGRAL HEXAL (WITHDRAWN: MYOCARDIAL INFARCTION)
Created by
admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL HEXAL (WITHDRAWN: ACUTE CORONARY SYNDROME)
Created by
admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL RATIOPHARM GMBH (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by
admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL ACINO (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by
admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL RATIOPHARM (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL ACINO PHARMA (WITHDRAWN: STROKE)
Created by
admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL SANDOZ (WITHDRAWN: STROKE)
Created by
admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL ACINO PHARMA (WITHDRAWN: MYOCARDIAL INFARCTION)
Created by
admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL 1A-PHARMA (WITHDRAWN: STROKE)
Created by
admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL SANDOZ (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL 1A PHARMA (WITHDRAWN: MYOCARDIAL INFARCTION)
Created by
admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL ACINO (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
GREPID (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by
admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL ACINO PHARMA (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL HEXAL (WITHDRAWN:
Created by
admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
GREPID (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL ACINO (AUTHORIZED: ACUTE CORONARY SYNDROME)
Created by
admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL APOTEX (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL RATIOPHARM (WITHDRAWN: MYOCARDIAL INFARCTION)
Created by
admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL HEXAL (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL APOTEX (AUTHORIZED: STROKE)
Created by
admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL ACINO PHARMA GMBH (WITHDRAWN: MYOCARDIAL INFARCTION)
Created by
admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL HEXAL (WITHDRAWN: STROKE)
Created by
admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL 1A PHARMA (WITHDRAWN: ACUTE CORONARY SYNDROME)
Created by
admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL SANDOZ (WITHDRAWN: MYOCARDIAL INFARCTION)
Created by
admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL RATIOPHARM GMBH (AUTHORIZED: ACUTE CORONARY SYNDROME)
Created by
admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
GREPID (AUTHORIZED: STROKE)
Created by
admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL 1A PHARMA (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL ACINO (AUTHORIZED: STROKE)
Created by
admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL RATIOPHARM GMBH (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL ACINO PHARMA GMBH (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL ACINO PHARMA GMBH (WITHDRAWN: STROKE)
Created by
admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL APOTEX (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by
admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
744256-69-7
Created by
admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
|
PRIMARY | |||
|
DBSALT002628
Created by
admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
|
PRIMARY | |||
|
SUB30714
Created by
admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
|
PRIMARY | |||
|
BL9VGG8BHW
Created by
admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
|
PRIMARY | |||
|
100000115443
Created by
admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
|
PRIMARY | |||
|
9847991
Created by
admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
|
PRIMARY | |||
|
DTXSID30225441
Created by
admin on Mon Mar 31 19:02:04 GMT 2025 , Edited by admin on Mon Mar 31 19:02:04 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |